Literature DB >> 2905033

Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.

M Guérin1, M Barrois, M J Terrier, M Spielmann, G Riou.   

Abstract

Tumor specimens from 116 untreated patients with primary breast carcinoma at different clinical stages were analyzed for the structure and/or the expression of c-myc and c-erbB-2/neu proto-oncogenes. An amplification of the c-myc proto-oncogene (3 to greater than 50 fold) was detected only in 6% of carcinomas, with no evidence of locus rearrangement. High c-myc RNA levels detected in 45% of tumors were found significantly (p less than 0.01) correlated with lymph node involvement. Amplification (3 to greater than 30 fold) of the c-erbB-2/neu gene was observed in 20% of cancers. A 5 kb c-erbB-2/neu gene transcript was detected in the 103 cancer specimens analyzed. High levels of transcripts were observed in 36% of tumors. Overexpression did not depend only on amplification since found in 14 tumor samples with a single gene copy. The gene amplification and overexpression were found significantly associated with cancers of poor prognosis. Moreover our data show that both proto-oncogenes are overexpressed only in 12.5% of tumor samples and suggest that each gene might play a different role in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2905033

Source DB:  PubMed          Journal:  Oncogene Res        ISSN: 0890-6467


  31 in total

1.  Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells.

Authors:  N E Hynes; D Taverna; I M Harwerth; F Ciardiello; D S Salomon; T Yamamoto; B Groner
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

2.  Cadmium promotes breast cancer cell proliferation by potentiating the interaction between ERalpha and c-Jun.

Authors:  Christina L Siewit; Bridget Gengler; Esera Vegas; Rachel Puckett; Maggie C Louie
Journal:  Mol Endocrinol       Date:  2010-03-10

3.  C-myc as a predictive marker for chemotherapy in metastatic breast cancer.

Authors:  Nataša Todorović-Raković; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Clin Exp Med       Date:  2011-11-24       Impact factor: 3.984

4.  c-myc reverses neu-induced transformed morphology by transcriptional repression.

Authors:  T C Suen; M C Hung
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

5.  Differential gene regulation by the SRC family of coactivators.

Authors:  Hua Zhang; Xia Yi; Xiaojing Sun; Na Yin; Bin Shi; Huijian Wu; Dan Wang; Ge Wu; Yongfeng Shang
Journal:  Genes Dev       Date:  2004-07-15       Impact factor: 11.361

Review 6.  Genetic alterations in primary breast cancer.

Authors:  R Callahan
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

7.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

8.  The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis.

Authors:  Gerald B W Wertheim; Thomas W Yang; Tien-chi Pan; Anna Ramne; Zhandong Liu; Heather P Gardner; Katherine D Dugan; Petra Kristel; Bas Kreike; Marc J van de Vijver; Robert D Cardiff; Carol Reynolds; Lewis A Chodosh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-28       Impact factor: 11.205

9.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

10.  Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Authors:  Amylou C Dueck; Monica M Reinholz; Xochiquetzal J Geiger; Kathleen Tenner; Karla Ballman; Robert B Jenkins; Darren Riehle; Beiyun Chen; Ann E McCullough; Nancy E Davidson; Silvana Martino; George W Sledge; Peter A Kaufman; Leila A Kutteh; Julie Gralow; Lyndsay N Harris; James N Ingle; Wilma L Lingle; Edith A Perez
Journal:  Clin Cancer Res       Date:  2013-08-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.